Kiniksa Pharmaceuticals International (KNSA) Current Deferred Revenue (2022 - 2024)

Kiniksa Pharmaceuticals International (KNSA) has reported Current Deferred Revenue for 3 consecutive years, with $31.8 million the latest figure, recorded in Q4 2024.

• For the quarter ending Q4 2024, Current Deferred Revenue rose 159.45% year-over-year to $31.8 million; the trailing twelve-month figure through Dec 2024 stood at $31.8 million (up 159.45% YoY), and the FY2024 full-year result was $31.8 million, up 159.45% from the prior year.
• Current Deferred Revenue climbed to $31.8 million in Q4 2024 per KNSA's latest filing, from $12000.0 in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $31.8 million in Q4 2024 and bottomed at $12000.0 in Q2 2024.
• Historically, Current Deferred Revenue has averaged $10.7 million across 3 years, with a median of $6.5 million in 2023.
• The widest YoY moves for Current Deferred Revenue: up 159.45% in 2024, down 99.74% in 2024.
• Over 3 years, Current Deferred Revenue stood at $12.0 million in 2022, then increased by 2.17% to $12.3 million in 2023, then soared by 159.45% to $31.8 million in 2024.
• According to Business Quant data, Current Deferred Revenue over the past three periods registered $31.8 million, $12000.0, and $156000.0 for Q4 2024, Q2 2024, and Q1 2024 respectively.